Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565758 | 0.98 | KDM4E (0.41) | KDM4EALDH1A1 | |
| SCHEMBL20118757 | 0.93 | KDM4E (0.42) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL25566721 | 0.90 | BCHE (0.35) | KDM4EALDH1A1 | |
| SCHEMBL12028002 | 0.88 | KDM4E (0.42) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL25565765 | 0.86 | ALDH1A1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL25075487 | 0.85 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL25565745 | 0.79 | HRH3 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL5002480 | 0.78 | MEN1 (0.41) | KDM4EALDH1A1SIGMAR1 | |
| SCHEMBL23977797 | 0.77 | MEN1 (0.33) | KDM4E | |
| SCHEMBL4609242 | 0.77 | ALDH1A1 (0.41) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TIBA BIOTECH LLC (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | TIBA BIOTECH LLC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149562-A1 | CARRIERS FOR EFFICIENT NUCLEIC ACID DELIVERY | POLN, TLR9, TSG101 | KDM4E 4832/4885ALDH1A1 3979/4885SIGMAR1 4124/4885 |
| US-11859201-B2 | Nanoparticle compositions containing sugar functionalized nucleic acid carriers | TLR9, TLR3, TSG101 | KDM4E 4820/4885ALDH1A1 3422/4885SIGMAR1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.